BMY Surges 2.65% on FDA Priority Review for Breyanzi's MZL Potential Trading 150th in $660M Volume as High-Volume Strategies Shine

Bristol-Myers Squibb (BMY) closed August 4, 2025, up 2.65% with a $0.66 billion trading volume, ranking 150th in market activity. The FDA accepted its supplemental biologics license application for Breyanzi (lisocabtagene maraleucel) to treat relapsed or refractory marginal zone lymphoma (MZL), granting Priority Review with a PDUFA decision date of December 5, 2025. This marks a potential milestone as Breyanzi could become the first CAR T cell therapy approved for MZL, a lymphoma affecting 7% of non-Hodgkin lymphoma cases. The application is supported by positive results from the TRANSCEND FL trial, showing durable responses and a consistent safety profile in MZL patients.

The FDA’s Priority Review accelerates regulatory timelines, which historically correlates with positive market reactions for drug approvals. Breyanzi’s existing approvals across multiple lymphoma indications, combined with its potential expansion into MZL, underscore Bristol-Myers Squibb’s leadership in cell therapy. The company emphasized streamlined monitoring requirements for Breyanzi, reducing barriers to adoption while maintaining safety, which could enhance market accessibility and adoption rates.

A backtested strategy of buying the top 500 high-volume stocks daily and holding for one day returned 166.71% from 2022 to 2025, outperforming benchmarks by 137.53%. This highlights the significance of liquidity concentration in volatile markets, where high-volume stocks like BMY may exhibit amplified short-term price movements due to institutional and algorithmic trading activity.